Compare iShares MSCI Australia ETF (EWA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares MSCI Australia ETF trades at $28.52 (market cap $1.17B), while Vertex Pharmaceuticals Incorporated trades at $510.05 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 109× iShares MSCI Australia ETF's market cap, and iShares MSCI Australia ETF is more actively traded (2,121,231 versus 1,487,944). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 63 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EWA | VRTX | |
|---|---|---|
Market Cap | $1.17B | $127.55B |
Volume | 2,121,231 | 1,487,944 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $557.96 |
52-Week Low | $24.95 | $407.37 |
Typical Hold Time | 63 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Australia ETF (EWA) trades at $28.465, up 0.83% today, but technical indicators signal a bearish trend with all moving averages in sell territory. The ETF, which tracks Australian equities, faces headwinds from domestic market volatility and inflation concerns, as Australian shares recently hit a three-month low. Key support and resistance cluster tightly around $28, indicating a critical price zone. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
Outlook remains cautious due to technical weakness and macroeconomic pressures, though some analysts see upside potential from commodity exposure. Risks include persistent inflation, tight monetary policy, and global economic shifts. Investors should weigh the bearish technicals against Australia's resource-driven economic prospects.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
